Hyfe Introduces AI-Powered Tool for Chronic Cough Care
Online, Friday, 11 April 2025.
Hyfe has launched a digital therapeutic using AI to treat chronic cough. The innovative tool offers personalized care and aims for global expansion, transforming respiratory healthcare.
Revolutionary AI-Driven Solution
Hyfe’s groundbreaking digital therapeutic combines AI-powered cough monitoring with Behavioral Cough Suppression Therapy (BCST), marking a significant advancement in respiratory healthcare [1]. The solution will first launch in Japan through a strategic partnership with KYORIN Pharmaceutical Co., Ltd., with plans for global expansion targeting conditions including COPD, asthma, and long COVID [2].
Technical Innovation in Respiratory Care
The technology leverages validated cough detection algorithms integrated with FDA-cleared multisensor technology for continuous, real-world monitoring [3]. This digital health solution provides privacy-first cough monitoring alongside comprehensive measurements of sleep and physical activity, offering superior accuracy and scalability for modern respiratory research [3]. As emphasized by Hyfe’s CEO Tamsin Chislett, this innovation removes traditional clinic barriers, making side-effect-free treatment globally accessible [1].
Addressing a Critical Healthcare Need
Chronic cough, defined as a persistent cough lasting more than eight weeks in adults, significantly impacts quality of life, causing sleep disturbances and social challenges [4]. The condition traditionally requires a combination of lifestyle modifications and medical interventions [4]. Hyfe’s digital therapeutic represents a breakthrough in treatment approach, offering continuous monitoring and personalized care plans [1][3].